These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10103200)

  • 21. In vitro and in vivo metabolism and pharmacokinetics of bis [(t-butyl)-S-acyl-2-thioethyl]-beta-L-2',3'-dideoxy-5-fluorocytidine monophosphate.
    Martin LT; Cretton-Scott E; Placidi L; Faraj A; Loi AG; Schinazi RF; McClure HM; Gosselin G; Imbach JL; Sommadossi JP
    Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):481-99. PubMed ID: 10772729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration.
    Patel IH; Levy RH; Bauer TG
    Epilepsia; 1975 Dec; 16(5):705-16. PubMed ID: 816644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
    Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
    Cundy KC; Sueoka C; Lynch GR; Griffin L; Lee WA; Shaw JP
    Antimicrob Agents Chemother; 1998 Mar; 42(3):687-90. PubMed ID: 9517952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
    Asif G; Hurwitz SJ; Obikhod A; Delinsky D; Narayanasamy J; Chu CK; McClure HM; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2424-9. PubMed ID: 17485498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.
    Le Guerhier F; Pichoud C; Guerret S; Chevallier M; Jamard C; Hantz O; Li XY; Chen SH; King I; Trépo C; Cheng YC; Zoulim F
    Antimicrob Agents Chemother; 2000 Jan; 44(1):111-22. PubMed ID: 10602731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition.
    Zhang X; Nieforth K; Lang JM; Rouzier-Panis R; Reynes J; Dorr A; Kolis S; Stiles MR; Kinchelow T; Patel IH
    Clin Pharmacol Ther; 2002 Jul; 72(1):10-9. PubMed ID: 12152000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks.
    Rajagopalan P; Boudinot FD; Chu CK; Tennant BC; Baldwin BH; Schinazi RF
    Antimicrob Agents Chemother; 1996 Mar; 40(3):642-5. PubMed ID: 8851586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulatory and antiviral activities of 2',3'-dideoxy-beta-L-cytidine and 2',3'-dideoxy-beta-L-5-fluorocytidine.
    Gagnon L; Nordstrom PA; Duchaine J; Jutras D; Hamel M; Barbeau D; Hooker E; Ashman C; Cammack N; Tse A
    Immunopharmacol Immunotoxicol; 1995 Feb; 17(1):17-32. PubMed ID: 7759770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis.
    Borg N; Ståhle L
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2174-7. PubMed ID: 9736530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of 2-fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virus.
    Williams PE; Muirhead GJ; Sereni D; Rousseau FS; Edelman K; Hooker M
    Br J Clin Pharmacol; 1993 Mar; 35(3):255-60. PubMed ID: 8385974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
    Schinazi RF; Mellors J; Bazmi H; Diamond S; Garber S; Gallagher K; Geleziunas R; Klabe R; Pierce M; Rayner M; Wu JT; Zhang H; Hammond J; Bacheler L; Manion DJ; Otto MJ; Stuyver L; Trainor G; Liotta DC; Erickson-Viitanen S
    Antimicrob Agents Chemother; 2002 May; 46(5):1394-401. PubMed ID: 11959574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys.
    Hernandez-Santiago BI; Chen H; Asif G; Beltran T; Mao S; Hurwitz SJ; Grier J; McClure HM; Chu CK; Liotta DC; Schinazi RF
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2589-97. PubMed ID: 15980324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of dose dependent kinetics of methyl salicylate-2-O-β-D-lactoside in rhesus monkeys after oral administration.
    He Y; Yan Y; Zhang T; Ma Y; Zhang W; Wu P; Song J; Wang S; Du G
    J Ethnopharmacol; 2015 Apr; 164():293-300. PubMed ID: 25571846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
    Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral activity, biochemistry, and pharmacokinetics of 3'-azido-2',3'-dideoxy-5-methylcytidine.
    Schinazi RF; Chu CK; Eriksson BF; Sommadossi JP; Doshi KJ; Boudinot FD; Oswald B; McClure HM
    Ann N Y Acad Sci; 1990; 616():385-97. PubMed ID: 1706574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro.
    Lin TS; Luo MZ; Liu MC; Zhu YL; Gullen E; Dutschman GE; Cheng YC
    J Med Chem; 1996 Apr; 39(9):1757-9. PubMed ID: 8627596
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2', 3'-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina).
    Tuntland T; Nosbisch C; Unadkat JD
    J Antimicrob Chemother; 1997 Nov; 40(5):687-93. PubMed ID: 9421317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of renal impairment on the pharmacokinetics of zalcitabine.
    Bazunga M; Tran HT; Kertland H; Chow MS; Massarella J
    J Clin Pharmacol; 1998 Jan; 38(1):28-33. PubMed ID: 9597556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.